This 24-month study is for children aged 3 to 12 with Autism Spectrum Disorder (ASD). It's testing if adding AdiaVita, a product made from umbilical cord blood stem cells and exosomes, to glutathione therapy can improve autism symptoms more than glutathione alone. You would be randomly assigned to one of two groups for the first three months: one receiving glutathione only, and the other receiving glutathione plus monthly intravenous (into a vein) AdiaVita. Both groups also use a topical glutathione cream at home. The study will track changes in autism symptoms using a parent-filled checklist (ATEC) and assessments from therapists or teachers. The main goal is to see how much the ATEC score changes after six months. This study is currently unclear on its recruitment status.

Study design

This is an interventional study with 100 planned participants, randomly assigned to receive either glutathione alone or glutathione plus AdiaVita during the initial three-month treatment phase.

What's involved

You would need to attend all scheduled visits, which include physical exams, vital sign checks, and adverse event reviews. Treatments involve monthly intravenous infusions and twice-daily at-home topical glutathione during the first three months.

Compensation

You would be responsible for a $12,000 study fee plus bloodwork costs, if applicable.

Follow-up

Participants will be followed for 24 months, with the primary outcome measured at Month 6.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.